Interferon beta-1a
As of the edition of 20 October 2026, Interferon beta-1a is a protein: marketed, first approved in 1996 (US); acts on IFNAR1 and IFNAR2; US protection ended in 2008.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Protein
- Brand name
- Avonex
- First approved
- 17 May 1996 (US)
- Approvals on record
- 11 in 2 regions
- Holder of the most recent approval
- Merck KGaA; 4 holders in all
- Registered trials
- 66, 8 stopped early
- Disease areas
- Immune system; Nervous system; Infections; Lungs and airways; Cancer; Digestive system
US protection
US protection ended in 2008.
US protection ended in 2008, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Biogen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 14 | 0 | 0 |
| Phase 1 | 8 | 8 | 0 | 0 |
| Phase 2 | 17 | 9 | 1 | 4 |
| Phase 3 | 11 | 8 | 1 | 2 |
| Phase 4 | 15 | 12 | 0 | 2 |
| All trials | 66 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Biogen | Applicant and Lead sponsor of trials | 1996 to now |
| Merck KGaA | Later holder and Lead sponsor of trials | 1998 to now |